A review of the data and circumstances that led to authorization in children ages 5 to 11 years.
Marissa Cavaretta, PharmD, BCPS, BCACP
Advertisement
Articles by Marissa Cavaretta, PharmD, BCPS, BCACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Developing a COVID-19 Vaccine Alternative
2
Generic Lenacapavir Could Cost as Little as $25 Per Person Annually
3
Real-World Data Reinforce Effectiveness and Safety of Fecal Microbiota Therapy for Preventing Recurrent C difficile
4
Early, Aggressive Treatment and Shorter Antibiotic Courses Shape Modern Pneumonia Discharge Practices
5
